Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization GlobeNewswire July 31, 2025 WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign's machine learning and modeling […]

InflaRx to Report Second Quarter 2025 Results on August 7, 2025 GlobeNewswire July 31, 2025 JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production GlobeNewswire July 31, 2025 NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has

MariMed's Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT Holdings GlobeNewswire July 31, 2025 NORWOOD, Mass., July 31, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed,” “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced a strategic agreement with TILT Holdings (“TILT”)

Flow Capital Announces a C$15.0M Investment in Common Wealth GlobeNewswire July 31, 2025 TORONTO, ON, July 31, 2025 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” or the “Company”) is pleased to announce a C$15.0 million senior secured note in Common Wealth Pension Services Inc. (dba “Common Wealth”), a SaaS company serving the

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease GlobeNewswire July 31, 2025 New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) 'time saved' by early-start ADAS-Cog13 difference: âˆ'5.43 (P = 0.0035), ADCS-ADL difference:

Laureate Education Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2025 Company Increases Full-Year 2025 Guidance GlobeNewswire July 31, 2025 MIAMI, July 31, 2025 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the second quarter

Plus Therapeutics Provides US Launch Update for its CNSide(R) Diagnostic GlobeNewswire July 31, 2025 CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden regional availability over the next 12 months HOUSTON, July 31, 2025 (GLOBE

Edible Garden Launches First-to-Market USDA Organic Hydroponic Basil, Reinforcing Leadership in Controlled Environment Agriculture (CEA) GlobeNewswire July 31, 2025 Breakthrough product merges sustainability, freshness, and modern consumer appeal in a visually engaging, waste-reducing format BELVIDERE, NJ, July 31, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a

DT Midstream Reports Strong Second Quarter 2025 Results GlobeNewswire July 31, 2025 DETROIT, July 31, 2025 (GLOBE NEWSWIRE) — DT Midstream, Inc. (NYSE: DTM) today announced second quarter 2025 reported net income of $107 million, or $1.04 per diluted share. For the second quarter of 2025, Operating Earnings were also $107 million, or $1.04 per